Novocure Ltd Aktie
Deine Einschätzung
Novocure Ltd Aktie
Was spricht für und gegen Novocure Ltd in den nächsten Jahren?
Pro
Kontra
Rendite von Novocure Ltd im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Novocure Ltd | -0,58 % | 0,67 % | 2,21 % | -61,07 % | -61,07 % | -83,00 % | -91,82 % |
| Ironwood Pharmaceuticals | -0,75 % | -0,75 % | -19,88 % | -36,67 % | -36,67 % | -76,94 % | -71,24 % |
| Iovance Biotherapeutics Inc. | -1,45 % | -1,00 % | 11,62 % | -65,65 % | -65,65 % | -59,91 % | -93,89 % |
| Alnylam Pharmace. | 0,41 % | 0,21 % | -12,93 % | 49,98 % | 49,98 % | 52,61 % | 218,06 % |
Kommentare
News
Novocure: Steady Ahead of Key Milestones
Here's our initial take on Novocure's (NASDAQ: NVCR) fiscal 2025 second-quarter financial report.
Novocure reported no surprises in its latest quarter, with revenue up 6% for the year and both
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable
Novocure to Report Second Quarter 2025 Financial Results
Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open.
Novocure management will host a conference call and





